Although HHT accounts for approximately one third of the ara-chidonic acid (AA) metabolites produced by stimulated platelets, no well defined function has been attributed to this platelet product. We report that HHT stimulates prostacyclin production by endothelial cells, and have identified the mechanism for this effect. In human umbilical venous endothelial cells HHT (0.5 and 1pM) stimulated prostacyclin (RIA for 6KPGF1α) by 32±10% (1 SE) and 42±13% (P14C] AA metabolism in fetal bovine aortic endothelial cells (FBAECs) was studied. 6KPGF1α was stimulated by 25±9% and 30±6% at HHT cones, of 0.5 and 1μM (P14c] AA revealed that HHT (1μM) did not affect the ionophore stimulated release of AA from FBAEC membrane lipids (29521±11837 cpm/well control vs 32458+8811 in HHT treated cells, mean ±1SD) kinetic analyses revealed that HHT affected vascular cyclooxygenase. HHT (1μM) increased Vmax in test microsomes (706±21 pmol/mg/min) when compared to controls (529±20; P6 platelets control vs 2.28±1.62 in HHT treated platelets). In platelets prelabelled with [ 1-14c] AA, HHT (1μM) also had no effect on AA release post thrombin stimulation (5794_423 cpm per 108 platelets control vs. 6135±612 for paired HHT treated cells). Conversion to cyclooxygenase metabolites was also not enhanced (2605±265 vs 2806±332 for test platelets). HHT thus stimulates vascular prostacyclin without a concomitant effect on platelet AA metabolism. Our findings may explain the discrepancies relative to prostacyclin production in atherosclerosis and diabetes. In these disorders while ex vivo production of prostacyclin by vascular tissue is decreased, in vivo production is elevated. HHT may also be an important local modulator of platelet plug formation and could play a protective antithrombotic role by its hitherto unrecognized effect on vascular prostacyclin.